Can LFMD sustain its earnings growth into Q1 2025?

**LifeMD's potential to sustain earnings growth into Q1 2025 appears promising**, considering the following points: 1. **Strong Telehealth Growth**: LFMD's telehealth segment is expected to generate between $205 million and $213 million, marking significant growth from 2024. This segment's remarkable 60% year-over-year growth in revenue for the fourth quarter underscores its strong performance. 2. **Successful Product Launches**: The company has had successful product launches, including a male hormone replacement therapy and a nationwide pharmacy licensed in 47 states. These initiatives are expected to bolster LifeMD’s market presence and drive future growth. 3. **Insurance Coverage Expansion**: There has been an improvement in insurance coverage for GLP-1 medications, with the approval rate for Zepbound increasing by 18 percentage points. This is a positive development for the company, potentially leading to increased demand for its services. 4. **Financial Outlook**: For the first quarter of 2025, LFMD expects total revenue between $61 million and $63 million, above the consensus of $60 million. The company forecasts revenue of $265 million to $275 million for the full year 2025, surpassing analyst expectations of $258 million. 5. **Subscriber Growth**: The company's telehealth active subscribers increased by 27% to approximately 275,000. This growth in subscribers, along with the expansion of its Medicare offerings, could contribute to sustained earnings growth. 6. **Market Position**: LFMD's strong market position, as evidenced by the growth of its weight management program and the successful performance of its subsidiary, Rex MD, which generated over $80 million in annualized revenue, suggests a solid foundation for continued growth. In conclusion, while there are challenges, such as declining gross margins and uncertainties in the compounded GLP-1 medication market, LFMD's strong telehealth growth, successful product launches, insurance coverage expansion, and optimistic financial outlook indicate a potential for the company to sustain its earnings growth into Q1 2025.